BlockR™ – ResistR™ – ProlifR™
Bio-Europe
Company broadens global reach to pursue scientific partnerships, licensing deals, and strategic transactions
Also worth a look: Mitolyn, Built Around the Purple Peel Exploit, has been Launched, Designed to Enhance Mitochondrial Health & Manage Weight and Out Today: “My Favorite Things” by Award-winning Vocalist Nicole Henry.
ALISO VIEJO, CA, UNITED STATES, October 6, 2026 /EINPresswire.com/ — GenBio Inc., a biotechnology firm moving IND research forward with compounds inspired by natural sources, today revealed its attendance at BIO-Europe 2026, the company’s second international partnering conference. Scheduled for November 9–11, 2026, the event takes place at Koelnmesse in Cologne, Germany.
GenBio’s involvement marks a further phase in its global business development push after its participation in the Asia Bio Partnering Forum. The organization plans to engage with pharmaceutical and biotech companies, investors, and prospective development collaborators to examine opportunities consistent with its research projects and business strategy.
BIO-Europe is referred to by its host as Europe’s biggest and most enduring partnering conference for the international biotech and biopharma sectors. The host notes a meeting community exceeding 5,800 participants from more than 3,200 companies located in over 60 nations. The gathering brings together biotech and pharmaceutical leaders, startup firms, investors, academic researchers, and industry support providers.
For GenBio, the conference offers a venue to present its nature-based research platform and examine potential scientific partnerships, licensing arrangements, asset exchanges, and wider strategic openings.
The company’s development pipeline comprises BlockR™, its anti-inflammatory research initiative; ResistR™, its antimicrobial resistance research initiative; and ProlifR™, its emerging oncology research initiative. These programs remain under investigation, and their progress relies on additional study and confirmation.
Through conference networking sessions, GenBio intends to find organizations whose scientific expertise, development assets, and commercial objectives align with its research. Early conversations will cover non-confidential program summaries, with access to proprietary scientific data handled under proper confidentiality agreements.
Taking part in BIO-Europe supports GenBio’s drive to establish connections across international markets while furthering its scientific work and intellectual property approach. Participation and networking discussions do not represent finalized deals or ensure any financing, licensing agreement, or acquisition.
Companies and investors interested in arranging a meeting with GenBio during BIO-Europe 2026 may reach out to the organization directly.
About GenBio Inc.
GenBio Inc. is a U.S.-headquartered biotechnology company dedicated to identifying and developing compounds inspired by nature. Its research focuses include inflammation, antimicrobial resistance, and oncology. GenBio aims to progress its initiatives through scientific investigation, intellectual property growth, and strategic alliances.
Developed by Nature. Identified, Refined and Formulated by GenBio.
For more information, visit https://genbioinc.com.
